Pharming Group Future Growth
Future criteria checks 4/6
Pharming Group is forecast to grow earnings and revenue by 52.9% and 12.4% per annum respectively while EPS is expected to grow by 54.5% per annum.
Key information
52.9%
Earnings growth rate
54.5%
EPS growth rate
Biotechs earnings growth | 31.3% |
Revenue growth rate | 12.4% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 18 Mar 2024 |
Recent future growth updates
Recent updates
Revenues Working Against Pharming Group N.V.'s (AMS:PHARM) Share Price
Feb 14Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?
Nov 11Pharming Group N.V. (AMS:PHARM) Shares Could Be 49% Below Their Intrinsic Value Estimate
Aug 23Health Check: How Prudently Does Pharming Group (AMS:PHARM) Use Debt?
Jun 20Is Pharming Group (AMS:PHARM) Using Too Much Debt?
Mar 16Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 41% Above Its Share Price
Feb 17We Think Pharming Group (AMS:PHARM) Can Manage Its Debt With Ease
Dec 08Is Pharming Group (AMS:PHARM) Using Too Much Debt?
Aug 05Pharming Group N.V. Just Missed EPS By 56%: Here's What Analysts Think Will Happen Next
Mar 21These Analysts Think Pharming Group N.V.'s (AMS:PHARM) Sales Are Under Threat
Mar 19Is Pharming Group (AMS:PHARM) Using Too Much Debt?
Feb 20Pharming Group N.V.'s (AMS:PHARM) Intrinsic Value Is Potentially 40% Above Its Share Price
Oct 29Pharming Group (AMS:PHARM) Seems To Use Debt Quite Sensibly
Jun 03Increases to CEO Compensation Might Be Put On Hold For Now at Pharming Group N.V. (AMS:PHARM)
May 12Is Pharming Group N.V.'s (AMS:PHARM) Recent Performance Tethered To Its Attractive Financial Prospects?
Mar 15Pharming Group (AMS:PHARM) Seems To Use Debt Rather Sparingly
Feb 15Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 375 | 45 | 63 | 56 | 4 |
12/31/2025 | 327 | 15 | 36 | 29 | 4 |
12/31/2024 | 285 | 1 | 27 | 20 | 4 |
12/31/2023 | 245 | -11 | 3 | -17 | N/A |
9/30/2023 | 219 | -22 | -4 | -24 | N/A |
6/30/2023 | 206 | -16 | 5 | -15 | N/A |
3/31/2023 | 202 | -2 | -3 | -1 | N/A |
12/31/2022 | 206 | 14 | 20 | 22 | N/A |
9/30/2022 | 204 | 30 | 25 | 33 | N/A |
6/30/2022 | 202 | 21 | 15 | 26 | N/A |
3/31/2022 | 202 | 11 | 17 | 31 | N/A |
12/31/2021 | 199 | 16 | 21 | 38 | N/A |
9/30/2021 | 200 | 22 | 29 | 43 | N/A |
6/30/2021 | 200 | 31 | 40 | 52 | N/A |
3/31/2021 | 202 | 37 | 59 | 70 | N/A |
12/31/2020 | 212 | 38 | 68 | 84 | N/A |
9/30/2020 | 212 | 44 | 70 | 85 | N/A |
6/30/2020 | 202 | 46 | 59 | 93 | N/A |
3/31/2020 | 202 | 42 | 53 | 84 | N/A |
1/1/2020 | 189 | 41 | 49 | 74 | N/A |
9/30/2019 | 175 | 38 | 48 | 70 | N/A |
6/30/2019 | 175 | 34 | 59 | 63 | N/A |
3/31/2019 | 158 | 29 | 54 | 57 | N/A |
12/31/2018 | 155 | 29 | 42 | 46 | N/A |
9/30/2018 | 152 | -29 | 57 | 63 | N/A |
6/30/2018 | 138 | -44 | 54 | 61 | N/A |
3/31/2018 | 128 | -80 | 44 | 52 | N/A |
12/31/2017 | 108 | -91 | 39 | 46 | N/A |
9/30/2017 | 76 | -53 | N/A | 14 | N/A |
6/30/2017 | 47 | -47 | N/A | -6 | N/A |
3/31/2017 | 31 | -21 | N/A | -13 | N/A |
12/31/2016 | 17 | -18 | N/A | -11 | N/A |
9/30/2016 | 12 | -16 | N/A | -18 | N/A |
6/30/2016 | 12 | -15 | N/A | -18 | N/A |
3/31/2016 | 13 | -14 | N/A | -18 | N/A |
12/31/2015 | 12 | -11 | N/A | -19 | N/A |
9/30/2015 | 29 | 8 | N/A | -3 | N/A |
6/30/2015 | 27 | 9 | N/A | -1 | N/A |
3/31/2015 | 23 | 10 | N/A | -3 | N/A |
12/31/2014 | 26 | -7 | N/A | -3 | N/A |
9/30/2014 | 6 | -29 | N/A | -19 | N/A |
6/30/2014 | 6 | -35 | N/A | -16 | N/A |
3/31/2014 | 11 | -35 | N/A | -14 | N/A |
12/31/2013 | 9 | -21 | N/A | -11 | N/A |
9/30/2013 | 19 | -15 | N/A | -8 | N/A |
6/30/2013 | 18 | -19 | N/A | -12 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: PHARM is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (0.8%).
Earnings vs Market: PHARM is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: PHARM is expected to become profitable in the next 3 years.
Revenue vs Market: PHARM's revenue (12.4% per year) is forecast to grow faster than the Dutch market (9.1% per year).
High Growth Revenue: PHARM's revenue (12.4% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if PHARM's Return on Equity is forecast to be high in 3 years time